Evaluating the Use of Digital Biomarkers to Test Treatment Effects on Cognition and Movement in Patients with Lewy Body Dementia

BACKGROUND: PRESENCE was a Phase 2 trial assessing mevidalen for symptomatic treatment of Lewy body dementia (LBD). Participants received daily doses (10, 30, or 75 mg) of mevidalen (LY3154207) or placebo for 12 weeks. OBJECTIVE: To evaluate if frequent cognitive and motor tests using an iPad app an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jian, Battioui, Chakib, McCarthy, Andrew, Dang, Xiangnan, Zhang, Hui, Man, Albert, Zou, Jasmine, Kyle, Jeffrey, Munsie, Leanne, Pugh, Melissa, Biglan, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2022
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535589/
https://www.ncbi.nlm.nih.gov/pubmed/35694933
http://dx.doi.org/10.3233/JPD-213126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535589/
https://www.ncbi.nlm.nih.gov/pubmed/35694933
http://dx.doi.org/10.3233/JPD-213126

Ejemplares similares